medical oncology newsroom
The Adrenal Gland and Its Response to Immunotherapy
William Robinson, MD, PhD, discusses the scientific theory behind why melanomas that metastasize to the adrenal gland don’t respond to checkpoint inhibitor and provides his recommendation for patients moving forward.
Erin Schenk, MD, PhD, Recipient of LUNGevity Award
Erin Schenk, MD, PhD, has been awarded the 10th annual LUNGevity Career Development Award which supports exceptional young researchers to augment the lung cancer research pipeline and advance the field.
Colorectal Cancer Among Young Populations
Chris Lieu, MD sits down with CBS Denver to discuss the importance of early screening in response to rising cases of colorectal cancer among young people.
CU Researchers Receive Prestigious SPORE Grant
“A very strong team of collaborators have helped us propel this into a successful collaborative science grant, this is teamwork at its best.” Antonio Jimeno, MD, PhD
How Screening for Lung Cancer Can Save Lives
Dr. Studts discusses why LDCT screening has been an underused resource despite reducing lung cancer mortality by twenty percent.
Endowed Chair in Pancreatic Cancer Research
The inspiration for this gift was the dedication, selflessness, and overall outstanding patient care provided by Drs. Chris Lieu and Jennifer Diamond.
Discussing the Importance of Access to Clinical Trials
Antonio Jimeno, MD, PhD, is working on a study to investigate disparities in clinical trials and increase the representation of underserved populations.
Stephen Keysar, PhD, Promoted to Associate Professor
We are pleased to announce the promotion of Dr. Stephen Keysar from Assistant Research Professor to Associate Research Professor.
Defining MET Amplification as Drivers for NSCLC
Dr. Camidge has participated in one of the largest efforts to prove that MET-inhibitor drugs are effective for treating patients with NSCLC driven by MET amplification.
New Hope for Women with Metastatic Breast Cancer
Traci Lyons, PhD, suggests semaphorin 7 may be particularly important in estrogen receptor (ER) positive breast cancer because cancer cells in ER-positive breast cancer have receptors that allow them to use the hormone estrogen to grow.